Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS).
about
Cytogenetic features in myelodysplastic syndromesIDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis.MDS prognostic scoring systems – past, present, and futureEfficacy and safety of CHG regimen (low-dose cytarabine, homoharringtonine with G-CSF priming) as induction chemotherapy for elderly patients with high-risk MDS or AML transformed from MDS.Integrative analysis of next generation sequencing for small non-coding RNAs and transcriptional regulation in Myelodysplastic SyndromesMyelodysplastic syndromes: diagnosis, prognosis, and treatment.The role of azacitidine in the management of myelodysplastic syndromes (MDS).The evaluation of the outcome in myelodysplastic patients by using non-cytogenetic prognostic scoresRevised international prognostic scoring system for myelodysplastic syndromes.Influence of Prognostic Factors on OverallSurvival in Myelodysplastic Syndromes.Idarubicin and cytarabine in combination with gemtuzumab ozogamicin (IAGO) for untreated patients with high-risk MDS or AML evolved from MDS: a phase II study from the EORTC and GIMEMA Leukemia Groups (protocol 06013).Non-hematologic predictors of mortality improve the prognostic value of the international prognostic scoring system for MDS in older adults.Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system.Myelodysplastic syndromes, aging, and age: correlations, common mechanisms, and clinical implications.Gene Expression and Methylation Pattern in HRK Apoptotic Gene in Myelodysplastic SyndromeDiagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet.Myelodysplastic syndromes: diagnosis and staging.Managing myelodysplastic symptoms in elderly patients.Myelodysplastic/myeloproliferative neoplasms, unclassifiable (MDS/MPN, U): natural history and clinical outcome by treatment strategy.Prognostic molecular markers in myelodysplastic syndromes.Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group.Recent advances in understanding the molecular pathogenesis of myelodysplastic syndromes.-7/7q- syndrome in myeloid-lineage hematopoietic malignancies: attempts to understand this complex disease entity.Biclonal myelodysplastic syndrome involving six chromosomes and monoallelic loss of RB1 - A rare case.Cytogenetic clonal evolution in myelodysplastic syndromes is associated with inferior prognosis.Iron overload in myelodysplastic syndromes (MDS) - diagnosis, management, and response criteria: a proposal of the Austrian MDS platformEffectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry.Myelodysplastic syndromes--many new drugs, little therapeutic progress.The impact of age on the diagnosis and therapy of myelodysplastic syndromes: results from a retrospective multicenter analysis in Germany.IDH mutations are closely associated with mutations of DNMT3A, ASXL1 and SRSF2 in patients with myelodysplastic syndromes and are stable during disease evolution.Comorbidity as prognostic variable in MDS: comparative evaluation of the HCT-CI and CCI in a core dataset of 419 patients of the Austrian MDS Study Group.Proposed score for survival of patients with myelodysplastic syndromes.Prognostic impact of age and gender in 897 untreated patients with primary myelodysplastic syndromes.Detailed analysis of clonal evolution and cytogenetic evolution patterns in patients with myelodysplastic syndromes (MDS) and related myeloid disorders.Analyzing transformation of myelodysplastic syndrome to secondary acute myeloid leukemia using a large patient database.Marrow fibrosis predicts early fatal marrow failure in patients with myelodysplastic syndromes.World Health Organization classification in combination with cytogenetic markers improves the prognostic stratification of patients with de novo primary myelodysplastic syndromes.A pilot study on the usefulness of peripheral blood flow cytometry for the diagnosis of lower risk myelodysplastic syndromes: the "MDS thermometer".Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
P2860
Q24644654-F4397555-F314-4FC0-9940-DE704B3723BCQ27851565-4FEFFE75-8DC8-47F3-9556-091055BE38F0Q28082460-2A6871DD-3366-4214-A80B-6813B03815E9Q33396739-3A3B667F-9F6A-4A81-92DE-9446E910B1C6Q33826865-FADCBE5D-E882-4696-9550-B9F3DB4BE404Q34389508-5DE42F6C-C2EE-455D-8D3C-AD1F80A761C7Q34418429-3034E3F6-B248-4C1A-A510-7EAEC9B480E2Q34520113-B385DD54-C44B-40CD-AABE-AC67744325A3Q34639717-3D612893-A430-4BC9-B229-0ECC6702087BQ34748960-6D639E36-61E1-4B1D-A3AC-9C78A26599C7Q36158816-3B6756B8-A45D-4B74-ADFE-B8ACC799C989Q36879957-EE32A834-940E-4373-AAF2-3E214039770DQ36920362-8FA2BBDA-323D-42C0-887F-248F4845B443Q36961721-EF14B42C-089E-4D01-BBCF-3D1CA6BBE9BEQ37099599-E03BD799-41DC-4827-A700-627737D5DCBDQ37263146-3FDD1F62-4E00-4966-8DE8-7E27EC6EECD8Q37277991-9278AECB-AA2F-4DF3-B2F0-B52832B0920CQ37448906-1892CB44-A5A9-4779-AB7D-A68BDFEFCA24Q37695094-1CE73457-67DB-4DA1-B1ED-7B26B316AF5EQ37810120-6A9BBB58-912B-4D68-B352-D678184A6A4CQ38037118-7FFA3BD8-9605-45DC-83B4-5AB1ABFACB22Q38122703-3E5BB0AB-52ED-4E43-AF94-FF696B1199FDQ38226741-A9B7DCA9-7445-484A-AAC8-2DF5D3EB548EQ38367179-E216B277-BE61-402D-8BA8-FC9AC2D83DFFQ38659921-8EF33C13-AB74-4DEE-9193-55C584FFA640Q39529378-A8B7458F-9B76-4FC0-8C1B-AC487372AA69Q40974681-B12836EC-BF3D-4D5C-BE62-EFB563FC2BAEQ42186622-54555E04-603D-4AD7-B00E-6498197F00DFQ44895438-B9FBB093-B4B0-4EFF-B90A-2F59B119F0CCQ45719667-C37EF355-0593-4876-9529-5060D51211B1Q45928400-C31BC11F-1E57-491A-BBBC-202002817583Q50717261-5682C113-691A-48BF-ADEC-1730E5E17446Q51626246-8AA98C4E-9D12-40E5-8DAB-5AE015CCCEBBQ52668587-C20D82AA-8036-4A1E-98F3-75AF4956305CQ53128934-99CCB672-C964-4B2C-A3DB-02CD754D35E4Q53225234-2D7C4FC0-1340-412C-8915-2C53ADB3F9C2Q53561569-2C911072-5309-4B3E-AEB1-F96292D3306EQ55177500-7B0E3689-CC90-4616-93F1-B705B54DFF3DQ55969986-8EFE73CB-B9AF-4331-A87F-BA57FDDA4591
P2860
Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS).
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Refinement of the internationa ...... elodysplastic syndromes (MDS).
@en
Refinement of the international prognostic scoring system
@nl
type
label
Refinement of the internationa ...... elodysplastic syndromes (MDS).
@en
Refinement of the international prognostic scoring system
@nl
prefLabel
Refinement of the internationa ...... elodysplastic syndromes (MDS).
@en
Refinement of the international prognostic scoring system
@nl
P2093
P2860
P356
P1433
P1476
Refinement of the internationa ...... elodysplastic syndromes (MDS).
@en
P2093
Fonatsch C
Gattermann N
Giagounidis AA
Hildebrandt B
P2860
P2888
P304
P356
10.1038/SJ.LEU.2403963
P577
2005-12-01T00:00:00Z